69738-32-5

Upstream product

• 75-21-8 oxirane 
• 91-16-7 1,2-dimethoxybenzene 
• 7417-21-2 2-(3,4-dimethoxyphenyl)ethyl alcohol 
• 13335-51-8 2-(2,3-dimethoxyphenyl)ethan-1-ol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 69738-33-6 C₁₀H₁₃IO₂ 
• 65144-89-0 5,6-dimethoxy-2-phenyl-1-tetralone 

Relevant academic research and scientific papers

Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 μM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 μM (or 3.7-19 μg/mL).

Substituted tetrahydroisoquinoline compounds, methods of making, and their use

The present invention relates to novel substituted tetrahydroisoquinoline compounds, pharmaceutical compositions containing the compounds, methods of making the compounds, and methods of using the compounds to destroy a target cell, such as a cancer cell,

Catechol carboxylic acids

The invention relates to catechol carboxylic acid derivatives of the formula STR1 wherein, R1 is STR2 acetyl, hydrogen, hydroxy or alkanoyloxy, R2 is STR3 hydroxy, hydrogen or alkanoyloxy, wherein R is hydrogen, lower alkyl or --(CH2)n --N--(lower alkyl)2, R3 is hydrogen, lower alkyl or amino, R4 is hydrogen, lower alkyl, halogen or amino A is STR4 wherein, R5 is hydrogen or acyl, R6 is hydrogen, halogen, lower alkyl, aryl or cycloalkyl, and R7 and R8, independently, are hydrogen, lower alkyl or halogen, or A is STR5 wherein, R5 is hydrogen or acyl, R9 is hydrogen, lower alkyl, R10 is hydrogen, lower alkyl or halogen, R11 is hydrogen, lower alkyl, cycloalkyl or halogen, m is 0 or 1, n is an integer of 2-10, provided, that no more than one of R1 or R2 can be hydroxy, alkanoyloxy or STR6 and when R is hydrogen, salts thereof with pharmaceutically acceptable bases or when R is --(CH2)n --N--(lower alkyl)2, salts thereof with pharmaceutically acceptable acids. The compounds of formula I are useful as agents for the treatment of inflammatory diseases such as arthritis, inflammatory bowel disease such as colitis, cardiovascular diseases such as myocardial ischemia, skin diseases such as psoriasis by topical administration, and bronchopulmonary diseases such as asthma.

Substituted naphthalene carboxylic acids

The invention relates to substituted naphthalene carboxylic acid derivatives of the formula STR1 wherein one of R1 and R2 is STR2 and the other is hydrogen, wherein R is hydrogen or lower alkyl, R10 is hydrogen or lower al